| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 579 | 2017 |
| Regulation of ER-mitochondria contacts by Parkin via Mfn2 V Basso, E Marchesan, C Peggion, J Chakraborty, S von Stockum, ... Pharmacological research 138, 43-56, 2018 | 176 | 2018 |
| Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS E Tasca, V Pegoraro, A Merico, C Angelini Clin. Neuropathol 35 (1), 22-30, 2016 | 89 | 2016 |
| Danon disease: review of natural history and recent advances G Cenacchi, V Papa, V Pegoraro, R Marozzo, M Fanin, C Angelini Neuropathology and Applied Neurobiology 46 (4), 303-322, 2020 | 76 | 2020 |
| Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration V Pegoraro, A Merico, C Angelini Journal of the Neurological Sciences 380, 58-63, 2017 | 60 | 2017 |
| Update on polyglucosan storage diseases G Cenacchi, V Papa, R Costa, V Pegoraro, R Marozzo, M Fanin, ... Virchows Archiv 475 (6), 671-686, 2019 | 35 | 2019 |
| MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients V Pegoraro, R Marozzo, C Angelini Clinical neuropathology 39 (3), 105, 2020 | 34 | 2020 |
| MyomiRNAs dysregulation in ALS rehabilitation V Pegoraro, A Merico, C Angelini Brain sciences 9 (1), 8, 2019 | 31 | 2019 |
| Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1 C Fritegotto, C Ferrati, V Pegoraro, C Angelini Neurological Sciences 38, 619-625, 2017 | 29 | 2017 |
| Current and emerging therapies in Becker muscular dystrophy (BMD) C Angelini, R Marozzo, V Pegoraro Acta Myologica 38 (3), 172, 2019 | 28 | 2019 |
| Hearing impairment in MELAS: new prospective in clinical use of microRNA, a systematic review A Di Stadio, V Pegoraro, L Giaretta, L Dipietro, R Marozzo, C Angelini Orphanet journal of rare diseases 13, 1-9, 2018 | 24 | 2018 |
| MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy V Pegoraro, P Cudia, A Baba, C Angelini Neurological Sciences 41 (10), 2953-2960, 2020 | 21 | 2020 |
| The MTHFR C677T polymorphism modifies age at onset in Parkinson’s disease A Vallelunga, V Pegoraro, M Pilleri, R Biundo, A De Iuliis, M Marchetti, ... Neurological Sciences 35, 73-77, 2014 | 20 | 2014 |
| Circulating miR-206 as a biomarker for patients affected by severe limb girdle muscle dystrophies V Pegoraro, C Angelini Genes 12 (1), 85, 2021 | 16 | 2021 |
| Morphological study of TNPO3 and SRSF1 interaction during myogenesis by combining confocal, structured illumination and electron microscopy analysis R Costa, MT Rodia, N Zini, V Pegoraro, R Marozzo, C Capanni, ... Molecular and Cellular Biochemistry 476, 1797-1811, 2021 | 15 | 2021 |
| MiRNAs, myostatin, and muscle MRI imaging as biomarkers of clinical features in becker muscular dystrophy R Marozzo, V Pegoraro, C Angelini Diagnostics 10 (9), 713, 2020 | 13 | 2020 |
| MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy V Pegoraro, S Missaglia, R Marozzo, D Tavian, C Angelini Muscle & Nerve 61 (2), 253-257, 2020 | 11 | 2020 |
| Diagnostic challenges in metabolic myopathies C Angelini, R Marozzo, V Pegoraro, S Sacconi Expert Review of Neurotherapeutics 20 (12), 1287-1298, 2020 | 10 | 2020 |
| A new family with transportinopathy: increased clinical heterogeneity C Angelini, R Marozzo, E Pinzan, V Pegoraro, MJ Molnar, A Torella, ... Therapeutic Advances in Neurological Disorders 12, 1756286419850433, 2019 | 10 | 2019 |
| Correlation between ETFDH mutations and dysregulation of serum myomiRs in MADD patients S Missaglia, V Pegoraro, R Marozzo, D Tavian, C Angelini European Journal of Translational Myology 30 (1), 2020 | 7 | 2020 |
